Date:7/13/2010

ile and side effects profile, and the Company's strategy for growth, product development, product launches regulatory approvals, market position, acquisitions, revenues, expenditures and other financial results, are forward-looking statements.   All forward-looking statements are based on current expectations and are subject to risk and uncertainties.  In connection with the "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.   Such factors include (but are not limited to) the following:

1. the ability to continue as a going concern;
2. difficulties and uncertainties with respect to obtaining additional capital, as more fully described in Part I, Item 2 – "Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" in the Quarter Report on Form 10-Q for the quarter ended December 31, 2009 (the third quarter of the Company's fiscal year ended March 31, 2010 (the "Form 10-Q");
3. the decisions the Company makes in order to maintain and increase our limited cash and final resources may result in significant charges for impairment of inventory, property and equipment and intangible and other long-lived assets and may affect the Company's commercial relationships with suppliers, vendors and other third parties, including their willingness to deal with the Company, including on acceptable terms;
4. the Company's ability to fund our operations beyond the quarter ending September 30, 2010, based on our current cash balance and estimates of our operating expenditures which, as previously d
   '/>"/>

SOURCE K-V Pharmaceutical Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Ferring Pharmaceuticals FIRMAGON® Named Official Sponsor of Ed Randalls Bat for the Cure
2. Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc.
3. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
4. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
5. K-V Pharmaceutical Company Receives Letter From New York Stock Exchange Regarding Delayed Filing of Its Annual Report on Form 10-K for Fiscal Year 2010
6. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
7. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
8. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
9. Federal Appeals Court Rules Pharmaceutical Sales Reps Entitled to Overtime Pay
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Optivar®
11. EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical